Trial Profile
An open-label, randomised, phase III Study cOmparing trifLuridine/tipiracil (S 95005) in combination with bevacizumab to capecitabine in combination with bevacizumab in firST-line treatment of patients with metastatIC colorectal cancer who are not candidatE for intensive therapy (SOLSTICE study)
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 13 Mar 2024
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Tipiracil/trifluridine (Primary) ; Capecitabine
- Indications Adenocarcinoma; Colon cancer; Colorectal cancer; Rectal cancer
- Focus Registrational; Therapeutic Use
- Acronyms SOLSTICE
- 10 Mar 2024 The study has been completed in Portugal, according to the European Clinical Trials Database record.
- 10 Oct 2023 Planned End Date changed from 18 Sep 2022 to 30 Jun 2024.
- 10 Oct 2023 Status changed from completed to active, no longer recruiting.